In collaboration with University of Utrecht researchers, an analysis of assessed indications in 4 Beneluxa countries was carried out: Austria, Belgium, Ireland and the Netherlands. For BE, IE and NL, the conclusions on added benefit and the reasons for any differences in...
The Beneluxa Initiative aims to ensure sustainable access
to innovative medicine at affordable cost for our patients.
Joint publication analysing the feasibility of joint HTA between Beneluxa countries
Beneluxa-ministers meet in the margin of EPSCO Health
The health ministers from the countries participating in the Beneluxa-initiative met during the EPSCO meeting on November 30th to exchange on their collaboration. Focus of their discussion were Managed Entry Agreements and External Reference Pricing. All ministers agree on the...
Joint Health Technology Assessment for Hemgenix
On 20 February 2023 the European Commission granted conditional approval for Hemgenix (etranacogene dezaparvovec), a gene therapy used to treat adults with severe and moderately severe haemophilia B, an inherited bleeding disorder caused by the lack of factor IX (a protein needed...